From Testing
to Targeted
Treatments (FT3)*

A collective program to make targeted medicine an accessible reality in oncology and beyond.

Our mission

FT3 is a global, open, and collaborative
multi-stakeholder program
. We bring together diverse stakeholders and activities to build
synergies and accelerate pragmatic efforts to make personalized medicine an accessible reality for all patients who could benefit from it, starting with cancer and testing.

The program uses a co-creation approach, building with patients for patients. We aim to accelerate the benefits of personalized medicine by generating better evidence, identifying, streamlining and scaling best practices to make them sustainable, creating awareness and building the conditions for better access to targeted medicine in oncology and beyond.

WHY is FT3 relevant?

Personalized and Precision Medicine can transform lives, but its potential benefits have not yet been fully realized.

The PM landscape is rapidly changing and fragmented. Efforts to expand it are piecemeal and disconnected.

Best practices are hard to identify, and lack of standardization on national and global levels is a challenge.

Patients are often unaware that better treatments may exist, and are not able to discuss these options with their doctors.

Even where treatments are available, barriers to access may prevent that treatment from being offered to patients.

Healthcare professionals may need support in interpreting data or in making clinical decisions and recommendations based on data

Do you believe you can contribute to making targeted testing and treatments a wide-spread reality in the health care?

An independent, nonprofit global coalition

contributing funding and/or expertise in-kind.



HTA bodies



Diagnostic companies

Pharmaceutical companies

Medical societies

Patient organizations

Founding members